ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,732.93
      0.25%
      US Tech 100
      19,426.00
      0.54%
      Dow Jones
      42,208.22
      0.20%
      Brent Oil
      74.345
      -0.29%
      Bitcoin
      64,538.90
      0.42%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Krystal Biotech Inc (KRYS) Quote

      Krystal Biotech Inc

      Krystal Biotech Inc (KRYS)

      NASDAQ
      179.47
      -0.71
      (-0.39%)
      Closed September 24 4:00PM
      Delayed by 15 minutes
      179.47
      -0.13
      (-0.07%)
      After Hours: 4:00PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      179.47
      Bid
      178.20
      Ask
      182.00
      Volume
      306,222
      176.225 Day's Range 181.03
      93.95 52 Week Range 219.34
      Market Cap
      5.156B
      Previous Close
      180.18
      Open
      181.03
      Last Trade
      3
      @
      174.72
      Last Trade Time
      Financial Volume
      $ 54,821,639
      VWAP
      179.0258
      Average Volume (3m)
      270,354
      Shares Outstanding
      28,729,950
      Dividend Yield
      -
      PE Ratio
      472.01
      Earnings Per Share (EPS)
      0.38
      Revenue
      50.7M
      Net Profit
      10.93M

      About Krystal Biotech Inc

      Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.krystalbio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $180.18. Over the last year, Krystal Biotech shares have traded in a share price range of $ 93.95 to $ 219.34.

      Krystal Biotech currently has 28,729,950 shares outstanding. The market capitalization of Krystal Biotech is $5.18 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 472.01.

      Ask ADVFN Intelligence (AI)

      KRYS Latest News

      More News

      FeaturedCannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

      14 hours ago

      FeaturedIntegrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.

      14 hours ago

      Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

      PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

      September 13 2024
      GlobeNewswire Inc.

      Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

      PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

      September 06 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      August 28 2024
      Edgar (US Regulatory)

      Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

      Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...

      August 28 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 05 2024
      Edgar (US Regulatory)

      Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

      Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study...

      August 05 2024
      GlobeNewswire Inc.

      U.S. Index Futures and Oil Prices Plunge on Recession Concerns

      U.S. index futures fell sharply after a volatile week, with the Nasdaq Composite entering correction territory due to recession concerns and uncertainties about Federal Reserve actions. At 04:37...

      August 05 2024
      IH Market News
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-17.51-8.88922733272196.98197.885179.47423441185.23560895CS
      4-20.09-10.067147725199.56206.97179.47264783190.65865317CS
      12-2.35-1.29248707513181.82219.34164.81270354193.74106358CS
      2611.666.94833442584167.81219.34144.0001326428179.68358562CS
      5265.1957.0441022051114.28219.3493.95338167153.04621749CS
      156122.56215.35758214756.91219.3438.8563273903111.30848423CS
      260132.57282.66524520346.9219.3431.8922276796.12380492CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MSSMaison Solutions Inc
      $ 1.58
      (120.98%)
      		101.72M
      BNZIBanzai International Inc
      $ 8.24
      (96.19%)
      		62.37M
      XHGXChange TED Inc
      $ 1.175
      (89.67%)
      		29.88M
      SEELSeelos Therapeutics Inc
      $ 0.295
      (55.26%)
      		335.52M
      WVEWave Life Sciences Ltd
      $ 8.18
      (53.18%)
      		15.73M
      BIVIBioVie Inc
      $ 1.1719
      (-58.15%)
      		2.87M
      GHSIGuardion Health Sciences Inc
      $ 6.55
      (-37.74%)
      		379.43k
      FCUVFocus Universal Inc
      $ 0.2371
      (-28.15%)
      		2.86M
      XPONExpion360 Inc
      $ 0.0861
      (-26.41%)
      		49.82M
      TOIIWOncology Institute Inc
      $ 0.0142
      (-24.06%)
      		58.76k
      NVDANVIDIA Corporation
      $ 120.87
      (3.97%)
      		354.91M
      SEELSeelos Therapeutics Inc
      $ 0.295
      (55.26%)
      		335.52M
      SQQQProShares UltraPro Short QQQ
      $ 7.65
      (-1.54%)
      		135.88M
      INTCIntel Corporation
      $ 22.81
      (1.11%)
      		113.11M
      MSSMaison Solutions Inc
      $ 1.58
      (120.98%)
      		101.72M

      KRYS Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      KRYS new 52 week high
      👍️0
      Monksdream Monksdream 5 months ago
      KRYS 10Q due 5/6
      👍️0
      Monksdream Monksdream 6 months ago
      KRYS over $30
      👍️0
      Monksdream Monksdream 7 months ago
      KRYS new 52 week high
      👍️0
      Monksdream Monksdream 1 year ago
      From Cathie Wood
      A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
      ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
      Research Associate
      Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

      Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
      👍️0
      wiredawg wiredawg 3 years ago
      Moving nicely today...
      👍️0
      wiredawg wiredawg 3 years ago
      Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
      👍️0
      wiredawg wiredawg 3 years ago
      In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

      👍️0
      wiredawg wiredawg 3 years ago
      30 Nov Tues releases this PR during evening after market close:

      https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
      👍️0
      wiredawg wiredawg 3 years ago
      29 Nov Mon after market closes release this PR:

      https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
      👍️0
      wiredawg wiredawg 3 years ago
      29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

      https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
      👍️0
      wiredawg wiredawg 3 years ago
      This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
      👍️0
      wiredawg wiredawg 3 years ago
      Holding well so far, why the pretty hard drop?
      👍️0
      wiredawg wiredawg 3 years ago
      Why are you surprised? Serious question, not being impudent...
      👍️0
      rynlrt rynlrt 3 years ago
      200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
      👍️0
      Fofo812 Fofo812 3 years ago
      Surprised it held up this long
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Large tutes holdings. Some taking huge gains before years end.
      👍️0
      rynlrt rynlrt 3 years ago
      Not sure this kind of gain is sustainable. May see a big pullback
      👍️0
      Fofo812 Fofo812 3 years ago
      3rd post
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
      👍️0
      Trophy Trophy 5 years ago
      ..
      👍️0

      Your Recent History

      NASDAQ
      KRYS
      Krystal Biotech
      Delayed Upgrade Clock